Canada markets closed

ALK-Abelló A/S (AKBLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
431.090.00 (0.00%)
At close: 2:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close431.09
Bid0.00 x 0
Ask0.00 x 0
Day's Range431.09 - 431.09
52 Week Range259.50 - 487.00
Avg. Volume0
Market Cap4.933B
Beta (5Y Monthly)0.33
PE Ratio (TTM)554.10
EPS (TTM)0.78
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 16, 2017
1y Target EstN/A
  • GlobeNewswire

    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

    ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 1.Details of the person discharging managerial responsibility / person closely associateda)NameBertil Lindmark2.Reason for the notificationa)Position/statusMember of the Board of Directorsb)Initial notification/amendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameALK-Abelló A/Sb)LEI529900SGCREUZCZ7P0204.Details of the transact

  • GlobeNewswire

    Six-month interim report (Q2) 2021

    ALK reports revenue up 13% with sales growth across its portfolio, outlook updated (unaudited) ALK’s revenue growth increased during Q2 on continued strong momentum for tablet sales and a recovery in sales of legacy products. ALK saw overall revenue growth of 13% for the quarter and tablet sales growth of 23% with better than expected earnings, despite a significant, planned increase in R&D spend. Based on year-to-date results, and improved forecasts for H2, ALK has upgraded its 2021 financial o

  • GlobeNewswire

    ALK upgrades its full-year financial outlook

    ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company is upgrading its full-year financial outlook especially with regards to increasing earnings to reflect an improved sales forecast, as well as cost savings and a minor adjustment to the anticipated timing of clinical development activities. As a result: Revenue is now expected to grow 10-12% in local currencies (previously: 9-12), to reflect an improved sales forecast. Tablet sales growth is now expected at 25% or slightl